Journal article

BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF

Yen Ying Lim, Stephanie Rainey-Smith, Yoon Lim, Simon M Laws, Veer Gupta, Tenielle Porter, Pierrick Bourgeat, David Ames, Christopher Fowler, Olivier Salvado, Victor L Villemagne, Christopher C Rowe, Colin L Masters, Xin Fu Zhou, Ralph N Martins, Paul Maruff

INTERNATIONAL PSYCHOGERIATRICS | CAMBRIDGE UNIV PRESS | Published : 2017

Abstract

BACKGROUND: The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism Met allele exacerbates amyloid (Aβ) related decline in episodic memory (EM) and hippocampal volume (HV) over 36-54 months in preclinical Alzheimer's disease (AD). However, the extent to which Aβ+ and BDNF Val66Met is related to circulating markers of BDNF (e.g. serum) is unknown. We aimed to determine the effect of Aβ and the BDNF Val66Met polymorphism on levels of serum mBDNF, EM, and HV at baseline and over 18-months. METHODS: Non-demented older adults (n = 446) underwent Aβ neuroimaging and BDNF Val66Met genotyping. EM and HV were assessed at baseline and 18 months later. Fasted blood samples were obtained from..

View full abstract

Grants

Funding Acknowledgements

Funding for the study was provided in part by the study partners (Commonwealth Scientific Industrial and research Organization (CSIRO), Edith Cowan University (ECU), Mental Health Research institute (MHRI), National Ageing Research Institute (NARI), Austin Health, CogState Ltd.). The study also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program (DCRC2), as well as funding from the Science and Industry Endowment Fund (SIEF) and the Cooperative Research Centre (CRC) for Mental Health, an Australian Government Initiative. YYL is currently funded by the NHMRC-ARC Dementia Research Development Fellowship.